Lupin Dental's €15m Round Turned Old Claims Into Equity at a 28% Lower Issue Price

Lupin Dental’s €15 million Series A was not a single new-money cheque. The French dental-robotics company’s June filings show €14.92 million of subscriptions split between €11.55 million in cash and €3.37 million of due claims settled by compensation. The 44,991 new ordinary shares were issued at €331.64 each, about 28% below the €460.53 price used for the company’s recent ordinary issues.

That combination makes the financing a capital reset as well as a growth round. DIGICUTO, the legal entity that uses the Lupin Dental name, increased its issued shares from 182,818 to 227,809. The new block represents 19.75% of the post-round count. The same shareholder decisions created a Strategic Committee with prior-approval powers over important strategic, economic, financial and operational decisions. Existing pre-emption and approval clauses were removed from the statutes and left to a shareholders’ pact.

The public announcement, reported by Tech Funding News and independently by RoboActu, describes a €15 million Series A led by Fynveur with a €10 million investment, participation from existing shareholders and private investors, and a Bpifrance loan. The filings add the financing mechanics that the announcement does not: part of the equity subscription retired company claims rather than bringing in cash.

The filed round separates cash from claims

The decisive numbers appear in the 29 June 2026 RNE realisation minutes for DIGICUTO, SIREN 850 067 877. The president recorded the full subscription of 44,991 Actions A at €331.64 per share, for €14,920,815.24 including the issue premium.

The same minutes identify two payment certificates. Crédit Agricole Alpes Provence certified €11,549,363 deposited for the company. A 23 June auditor certificate covered €3,371,452.24 paid by compensation with liquid, due claims on DIGICUTO. The split is therefore approximately 77.4% cash and 22.6% claim setoff. It is not an allocation by named investor: the subscriber table is anonymised.

The distinction matters because a claim converted into shares does not extend runway in the same way as cash. It can reduce an obligation and put the claim holder into the equity base, but it does not provide the company with the funds represented by that claim. Conversely, the €11.55 million cash certificate is a direct liquidity event for DIGICUTO, although the public record does not disclose closing costs or the final use of funds.

The record also shows a separate, smaller claim conversion. Four hundred BSA 2023 were exercised at €230.26 each, with €92,104 settled by compensation. That exercise is not part of the €14.92 million Actions A subscription, but it reinforces the broader pattern: creditors or service providers can move from claims into ordinary shares when the company’s financing documents permit it.

The issue price reset the financing reference point

The €331.64 issue price is not a stated valuation, and the filings do not say that DIGICUTO accepted a 28% valuation markdown. It is an issue-price comparison. The company’s updated statutes record repeated ordinary issues in 2024, 2025 and early 2026 at €460.53 per share. Dividing €331.64 by €460.53 shows a decline of approximately 27.99%.

That is a meaningful change in the price at which new equity entered the register. It may reflect a negotiated round price, a change in financing context, or rights agreed outside the statutes. The available documents do not explain the rationale. They do establish that the June Actions A were issued below the price used for the recent ordinary issuances.

This is why the filing should not be turned into a headline valuation claim. A mechanical illustration using the documented counts and prices produces about €84.19 million for the pre-round count at €460.53 and €75.55 million for the post-round count at €331.64. Those figures are not a pre-money or post-money valuation. They ignore different rights, timing, the claim-setoff component, the Bpifrance loan, options and any shareholder-agreement terms. The useful conclusion is narrower: the registered issue price moved down while the share denominator moved up.

For investors, that combination changes the diligence question. A lower issue price can make a financing easier to close, but it also establishes a reference point for subsequent rounds, employee awards and conversion negotiations. The company’s economic performance, regulatory progress and the rights attached to the new shares determine whether the lower price is a temporary entry point or a more durable reset.

The denominator moved by nearly one-fifth

Before the financing, DIGICUTO had €1,828.18 of capital divided into 182,818 shares. The realisation minutes record a €449.91 nominal increase and 44,991 new shares. After closing, capital stood at €2,278.09 divided into 227,809 shares. The arithmetic is exact: 44,991 divided by 227,809 equals 19.749%.

Existing holders who did not subscribe therefore represented 80.251% of the post-round issued-share count, compared with 100% before the issue. That is simple issued-share dilution, not a fully diluted ownership calculation. The anonymised subscriber table prevents a public allocation of the new block among Fynveur, existing holders, private investors, claim holders or any other participant.

The 23 June 2026 unanimous shareholder decision also says that the Actions A were ordinary shares, fully paid at subscription, and assimilated to the existing ordinary shares. That language supports the share-count calculation. It does not reveal the private pact, side letters or commercial arrangements that may affect economic outcomes.

The filings record other capital movements immediately before the round. On 19 June, 1,500 free shares were acquired definitively by Paul Roberts after a presence-condition waiver, and 400 BSA 2023 were exercised by an anonymised beneficiary. Those actions increased the pre-round count to 182,818. They matter for the denominator, but they do not identify the Series A investors or prove any individual founder outcome.

Governance moved into a Strategic Committee and a pact

The financing decisions changed more than the share count. They created a Strategic Committee as an internal governance body. The shareholder extract says the committee is to consider the company’s major strategic, economic, financial and operational directions and approve certain important or structuring decisions in advance. The first members include the two co-founders, Michel Mayer representing ALVECTIS PE, Frederic Stolar representing Financière Spartacus, Olivier Gueymard, Philippe Veran and Jeroen van Heeswijk. Julien Miara was named an observer.

The committee does not represent DIGICUTO to third parties unless the president or a director general gives a specific delegation. That keeps the legal boundary clear. Its prior-approval role nevertheless creates a formal channel for influence over decisions that can determine how new capital is spent, when further equity is issued and how the operating plan is executed.

At the same time, the associates deleted the statutory pre-emption and approval clauses. The extract says transfer rules will now be organised mainly by the shareholders’ pact. That is a control shift in the architecture of the company, not proof that any named investor has unilateral control. The pact is private, and the filing does not disclose voting thresholds, reserved matters, board appointment rights or exit preferences.

The shareholder decision authorised up to 3,924 additional Actions A at the same €331.64 price, for a maximum subscription amount of €1,301,355.36, subject to prior Strategic Committee approval. The delegation was stated to run until 31 July 2026 and was reserved for private investors acting for their own account. It is an issuance envelope, not evidence that those shares were actually issued. A later filing would be needed to confirm whether it was used.

What the public announcement leaves unresolved

The company and independent coverage support the event: Lupin Dental closed a €15 million Series A, Fynveur invested €10 million, Bpifrance provided a loan, and Invus joined the board. The RNE documents add a more specific registered figure of €14.92 million for the equity subscription. The difference is not a contradiction. The announced amount includes a financing package that the filings do not need to describe as one number, and the loan is separate from the share issue.

The unresolved questions are commercial, not merely clerical. Which claim holders received the 2,844 or more shares settled through compensation? Did Fynveur’s €10 million investment correspond to a particular anonymised subscription line, or was it split across instruments? What rights were agreed in the shareholders’ pact after the statutory transfer clauses were removed? Did the additional 3,924-share envelope close before its 31 July expiry?

The public record also cannot establish a post-money valuation, investor percentages, founder dilution beyond the aggregate denominator, or the terms of the Bpifrance loan. The €331.64 price could be a negotiated early-stage price rather than evidence of distress. The company’s filings report a corrected 2024 net loss of €3.96 million and accumulated negative retained earnings of €7.45 million, but those figures alone do not establish insolvency or explain the round price.

The most defensible reading is therefore precise. Lupin Dental’s Series A combined cash financing with a material conversion of due claims into ordinary equity, issued a new 19.75% share block at a price about 28% below recent ordinary issues, and installed a Strategic Committee whose approval powers sit alongside a shareholders’ pact. The next document to watch is the post-round shareholder and pact package that identifies the anonymised subscribers, allocates the claim conversion and shows how the committee’s approval rights work in practice.

For investors and founders, the lesson is straightforward: the €15 million headline describes the size of the financing package, not one homogeneous form of value. The cash, the retired claims, the lower issue price and the governance reset each carry a different consequence. Reading them together is the difference between seeing a growth round and seeing how the capital stack was rebuilt.

Sources

• Lupin Dental legal notice identifies DIGICUTO as the legal company, the Lupin Dental commercial name and SIREN 850 067 877.
• Tech Funding News reports the 28 August 2026 €15 million Series A, Fynveur’s €10 million investment, Bpifrance loan and Invus board role.
• RoboActu independently reports the round structure and Lupin Dental’s supervised dental-robotics system.
• 29 June 2026 RNE realisation minutes record the €14,920,815.24 subscription, cash certificate, claim compensation, 44,991 shares and post-round capital.
• 23 June 2026 RNE unanimous shareholder decision records the issue terms, prior capital movements, Strategic Committee and future issuance delegation.
• This analysis also links to Callosum’s filed preferred-share financing, which separates a public round headline from a registered share issue and governance change.